Orapenem

Shooting for PhIII, Spero tees up a new lead antibiotic in-licensed cheap as it lines up $86M IPO
Endpoints
Wed, 10/11/17 - 10:00 am
Spero
antibiotics
clinical trials
Orapenem
SPR994